Cited by 104Dementia and Cognitive Impairment ResearchTelomeres, Telomerase, and SenescenceCognitive Abilities and Testing

Shorter Telomeres May Mark Early Risk of Dementia: Preliminary Analysis of 62 Participants from the Nurses' Health Study

Open access
Grodstein, Francine, van Oijen, Marieke, Irizarry, Michael C., Rosas, H. Diana, Hyman, Bradley T., Growdon, John H., De Vivo, Immaculata·2008·PLoS ONE

Abstract

BACKGROUND: Dementia takes decades to develop, and effective prevention will likely require early intervention. Thus, it is critical to identify biomarkers of preclinical disease, allowing targeting of high-risk subjects for preventive efforts. Since telomeres shorten with age and oxidative stress, both of which are important contributors to the onset of dementia, telomere length might be a valuable biomarker. METHODOLOGY/PRINCIPAL FINDINGS: Among 62 participants of the Nurses' Health Study, we conducted neurologic evaluations, including patient and caregiver interviews, physical exam, neurologic exam, and neuropsychologic testing. We also conducted magnetic resonance imaging (MRI) in a sample of 29 of these women. In these preliminary data, after adjustment for numerous health and lifestyle factors, we found that truncated telomeres in peripheral blood leukocytes segregate with preclinical dementia states, including mild cognitive impairment (MCI); the odds of MCI were 12-fold higher (odds ratio = 12.00, 95% confidence interval 1.24-116.5) for those with shorter telomere length compared to longer telomere length. In addition, decreasing telomere length was strongly related to decreasing hippocampal volume (p = 0.038). CONCLUSIONS: These preliminary data suggest that telomere length may be a possible early marker of dementia risk, and merits further study in large, prospective investigations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0001590

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Grodstein, F., van Oijen, M., Irizarry, M. C., Rosas, H. D., Hyman, B. T., Growdon, J. H., & De Vivo, I.
Affiliations
  • Brigham and Women's Hospital (US)
  • GlaxoSmithKline (United States) (US)
  • Harvard University (US)
Corresponding author
Grodstein, Francine
Venue
PLoS ONE
Published
2008-02-13
Volume
3
Issue
2
Pages
e1590
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2031002692
Cited by
104
References
13
Citations by year
2026: 3 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 12 · 2019: 5 · 2018: 7 · 2017: 7 · 2016: 4 · 2015: 9 · 2014: 8 · 2013: 6 · 2012: 10
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
Funders
  • National Institutes of Health (CA 87969, AG05134)
  • National Institute on Aging (AG15424, R01AG015424, P50AG005134, AG 05134)
  • National Cancer Institute (CA-87969, P01CA087969)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Cognitive Abilities and Testing
Keywords
telomere length, dementia risk, preclinical dementia, mild cognitive impairment, biomarkers, hippocampal volume, leukocytes, oxidative stress, aging, dementia prevention, Nurses' Health Study
MeSH terms
Aged, Cognition Disorders, Dementia, Female, Hippocampus, Humans, Leukocytes, Organ Size, Pilot Projects, Predictive Value of Tests, Logistic Models, Telomere

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review